2011-2021 年中国东南地区癌症生存趋势：基于人群的研究
IF 3.4
2区 医学
Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
引用次数: 0
摘要
目的：与发达国家相比，中国癌症患者的 5 年生存率较低，且不同地区之间差异较大。本研究旨在分析 2011 年至 2021 年期间中国东南部地区癌症患者的 5 年相对生存率：我们利用了中国福建省 12 个癌症登记处的人口统计数据。研究人群数据截至 2019 年 12 月 31 日，生存结果状态截至 2021 年 12 月 31 日。我们使用 ICD-10 和 ICD-O-3 对所有癌症病例进行分类。我们分析了合并癌症和不同癌症类型的 5 年相对生存率，并按性别、城市和农村地区以及年龄进行了分层。生存率估计值根据日历期（2011- 13年、2014- 15年、2016- 18年和2019- 21年）进行分层：最终，共有 160 294 名癌症患者参与了研究。在2011- 13年、2014- 15年、2016- 18年和2019- 21年，合并癌症的年龄标准化5年相对生存率分别为29.1%（95% CI：28.6- 29.7）、31.5%（95% CI：31.0- 32.0）、36.8%（95% CI：36.4- 37.3）和39.1%（95% CI：38.7- 39.6）。肺癌、前列腺癌、喉癌、结肠直肠癌、肾癌和骨癌的年龄标准化 5 年相对生存率分别增加了 4.3%、4.0%、3.8%、3.4%、3.4% 和 2.70%。2019-21年5年相对生存率较高（> 60%）的癌症包括甲状腺癌、睾丸癌、乳腺癌、膀胱癌、宫颈癌、前列腺癌和子宫癌。2019-2021年的5年生存率女性高于男性（47.8%对32.0%），城市地区高于农村地区（41.7%对37.1%）。相对生存率随着年龄的增长而下降：结论：2011 年至 2021 年期间，福建省的癌症 5 年生存率有所上升，但仍处于较低水平。建立强大的基层公共卫生体系可能是减轻福建省癌症负担的关键一步。本文章由计算机程序翻译，如有差异，请以英文原文为准。
Cancer Survival Trends in Southeastern China, 2011–2021: A Population-Based Study
Purpose: The 5-year cancer survival rate among Chinese patients is lower than that among patients in developed countries and varies widely across geographic regions. The aim of this study was to analyse the 5-year relative cancer survival rate in southeastern China, between 2011 and 2021.
Patients and Methods: We utilised population-based statistics from 12 cancer registries in Fujian, China. Study population data were up to date as of Dec 31, 2019, and survival outcome status was updated as of Dec 31, 2021. We used the ICD-10 and the ICD-O-3 to categorize all cancer cases. We analysed the 5-year relative survival for cancers combined and different cancer types stratified by sex, urban and rural areas, and age. Survival estimates were stratified according to calendar period (2011– 13, 2014– 15, 2016– 18 and 2019– 21).
Results: Ultimately, a total of 160,294 cancer patients were enrolled in the study. In 2011– 13, 2014– 15, 2016– 18 and 2019– 21, the age-standardised 5-year relative survival for cancers combined were 29.1% (95% CI: 28.6– 29.7), 31.5% (95% CI: 31.0– 32.0), 36.8% (95% CI: 36.4– 37.3) and 39.1% (95% CI: 38.7– 39.6), respectively. The age-standardised 5-year relative survival for lung, prostate, larynx, colon-rectum, kidney and bone cancers increased 4.3%, 4.0%, 3.8%, 3.4%, 3.4% and 2.70%, respectively. Cancers with high 5-year relative survival rates (> 60%) in 2019– 21 included thyroid, testis, breast, bladder, cervix, prostate and uterus cancers. The 5-year survival rates in 2019– 2021 was higher for females than for males (47.8% vs 32.0%) and higher in urban areas than in rural areas (41.7% vs 37.1%). Relative survival rates decreased with increasing age.
Conclusion: The 5-year cancer survival in Fujian Province increased between 2011 and 2021 but remained at a low level. Building a strong primary public health system may be a key step in reducing the cancer burden in Fujian Province.
Keywords: relative survival, cancer, population-based study, cancer registry
Patients and Methods: We utilised population-based statistics from 12 cancer registries in Fujian, China. Study population data were up to date as of Dec 31, 2019, and survival outcome status was updated as of Dec 31, 2021. We used the ICD-10 and the ICD-O-3 to categorize all cancer cases. We analysed the 5-year relative survival for cancers combined and different cancer types stratified by sex, urban and rural areas, and age. Survival estimates were stratified according to calendar period (2011– 13, 2014– 15, 2016– 18 and 2019– 21).
Results: Ultimately, a total of 160,294 cancer patients were enrolled in the study. In 2011– 13, 2014– 15, 2016– 18 and 2019– 21, the age-standardised 5-year relative survival for cancers combined were 29.1% (95% CI: 28.6– 29.7), 31.5% (95% CI: 31.0– 32.0), 36.8% (95% CI: 36.4– 37.3) and 39.1% (95% CI: 38.7– 39.6), respectively. The age-standardised 5-year relative survival for lung, prostate, larynx, colon-rectum, kidney and bone cancers increased 4.3%, 4.0%, 3.8%, 3.4%, 3.4% and 2.70%, respectively. Cancers with high 5-year relative survival rates (> 60%) in 2019– 21 included thyroid, testis, breast, bladder, cervix, prostate and uterus cancers. The 5-year survival rates in 2019– 2021 was higher for females than for males (47.8% vs 32.0%) and higher in urban areas than in rural areas (41.7% vs 37.1%). Relative survival rates decreased with increasing age.
Conclusion: The 5-year cancer survival in Fujian Province increased between 2011 and 2021 but remained at a low level. Building a strong primary public health system may be a key step in reducing the cancer burden in Fujian Province.
Keywords: relative survival, cancer, population-based study, cancer registry
求助全文
通过发布文献求助，成功后即可免费获取论文全文。
去求助
来源期刊
Clinical Epidemiology
Medicine-Epidemiology
CiteScore
6.30
自引率
5.10%
发文量
169
审稿时长
16 weeks
期刊介绍：
Clinical Epidemiology is an international, peer reviewed, open access journal. Clinical Epidemiology focuses on the application of epidemiological principles and questions relating to patients and clinical care in terms of prevention, diagnosis, prognosis, and treatment.
Clinical Epidemiology welcomes papers covering these topics in form of original research and systematic reviews.
Clinical Epidemiology has a special interest in international electronic medical patient records and other routine health care data, especially as applied to safety of medical interventions, clinical utility of diagnostic procedures, understanding short- and long-term clinical course of diseases, clinical epidemiological and biostatistical methods, and systematic reviews.
When considering submission of a paper utilizing publicly-available data, authors should ensure that such studies add significantly to the body of knowledge and that they use appropriate validated methods for identifying health outcomes.
The journal has launched special series describing existing data sources for clinical epidemiology, international health care systems and validation studies of algorithms based on databases and registries.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
